Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 88/100

Oral selective estrogen receptor modulator (SERM) that stimulates pituitary LH and FSH to double endogenous testosterone production while preserving testicular size and spermatogenesis.

Knowledge Graph:Vector: EndocrineIntercellular SignalingStem Cells
Head-to-Head CompareAudit in Stack
Longevity TherapeuticsEndocrineSilver Tier85–941stin Endocrine of 1203rdin Libido of 7Top 10in Stem Cells of 17High Confidence (Human RCTs)📈 Scientific Consensus: Rising

Enclomiphene Citrate (Selective Estrogen Receptor Modulator)

Oral selective estrogen receptor modulator (SERM) that stimulates pituitary LH and FSH to double endogenous testosterone production while preserving testicular size and spermatogenesis.

88/100
High Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Oral selective estrogen receptor modulator (SERM) that stimulates pituitary LH and FSH to double endogenous testosterone production while preserving testicular size and spermatogenesis.

2. Major Unanswered Scientific Uncertainty

Optimal dose-response curve and long-term human trial replication remain under ongoing investigation.

Strongest Supporting TrialPMID:23879796

Oral enclomiphene citrate stimulates the secretion of luteinizing hormone and testosterone while maintaining normal sperm counts in men with secondary hypogonadism

Randomized Double-Blind Phase II Multicenter Trial • Sample: 124 men with secondary hypogonadism

“Oral enclomiphene citrate raised serum testosterone from 248 ng/dL to 604 ng/dL while preserving normal sperm counts, avoiding the severe oligospermia seen with topical testosterone gel.”

Strongest Counter-Evidence / RiskPMID:23879796

Oral enclomiphene citrate stimulates the secretion of luteinizing hormone and testosterone while maintaining normal sperm counts in men with secondary hypogonadism: a randomized, double-blind, multicenter, phase II study

DOUBLE BLIND RCT

“Proved in a multicenter randomized double-blind Phase II trial that oral enclomiphene citrate raises endogenous testosterone and gonadotropins (LH/FSH) to normal physiological ranges while preserving normal testicular spermatogenesis, completely avoiding the azoospermia caused by exogenous TRT.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Multi-center randomized double-blind trial over 12-24 months.
Expected Impact: Establish standardized clinical practice guidelines.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Synergistic Target (30-64)
65/ 100

Oral SERM maintains normal lipid metabolism and avoids the supraphysiological polycythemia often triggered by exogenous testosterone esters.

HDL-CTriglyceridesHematocrit

Brain Longevity & Cognition

Synergistic Target (30-64)
78/ 100

Normalizes androgen levels supporting cerebral monoamine synthesis and central neuroendocrine vitality without estrogen deprivation.

Morning Fatigue ScoresExecutive Focus

Metabolic & Glycemic Health

Synergistic Target (30-64)
82/ 100

Elevates bioavailable androgens which promote lipolysis in visceral adipocytes and stimulate skeletal muscle glucose transporter GLUT4 expression.

Fasting GlucoseHOMA-IRVisceral Fat

Cancer Defense & Autophagy

Marginal Impact (5-29)
60/ 100

Preserves physiological androgen homeostasis without extreme spikes; binds selectively without excessive prostatic stimulation.

PSA (Prostate Specific Antigen)

Endocrine Vitality & Anabolic Tone

Foundational Target (65-100)
96/ 100

Blocks nuclear estrogen receptors in the pituitary and hypothalamus, eliminating estrogenic negative feedback to stimulate pulsatile LH and FSH secretion and endogenous Leydig cell steroidogenesis.

Total Serum TestosteroneFree TestosteroneLuteinizing Hormone (LH)Follicle-Stimulating Hormone (FSH)

Systemic Inflammation Suppression

Synergistic Target (30-64)
70/ 100

Eugonadal testosterone levels downregulate inflammatory cytokine transcription in monocyte-macrophage lineages.

hs-CRPTNF-alpha

Bone Density & Connective Matrix

Synergistic Target (30-64)
84/ 100

Sustains aromatizable substrate for local bone microenvironment estrogen production while stimulating androgenic mechanosensory bone remodeling.

Bone Mineral Density (DEXA)Osteocalcin

Cellular Longevity & Epigenetics

Synergistic Target (30-64)
76/ 100

Unlike exogenous testosterone, enclomiphene maintains Sertoli cell nourishment and gametogenic stem cell longevity.

Sperm MotilitySpermatogonial Stem Density
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:HPG Axis Disinhibition & Serum Testosterone Restoration
Secondary Clinical Endpoints:
Preservation of Intratesticular Testosterone & SpermatogenesisAppendicular Musculoskeletal StrengthMetabolic Glycemic BufferingLibido & Energy Renewal
LEVL Recommended Tracking Metrics:
StrengthEnergyLibidoMood

Libido

daily wellbeing
88/99
High EffectGrade A (Human RCTs)2-4 weeks
Enclomiphene citrate stimulates serum testosterone in men with secondary hypogonadismPMID: 25055002

Clinical Endpoint: Doubled mean total testosterone while avoiding testicular atrophy or exogenous suppression.

libido

Strength

daily wellbeing
86/99
High EffectGrade A (Human Phase II/III Trials)4-6 weeks
Oral enclomiphene citrate stimulates the secretion of LH and testosterone while maintaining normal sperm countsPMID: 23879796

Clinical Endpoint: Raised serum total testosterone from 248 ng/dL to 604 ng/dL with marked improvements in lean mass and strength.

strength

Overall Energy

daily wellbeing
85/99
High EffectGrade A (Human RCTs)2-4 weeks
Secondary Hypogonadism Energy & Fatigue ResolutionPMID: 23879796

Clinical Endpoint: Statistically significant improvement in DISF-SR and somatic vitality subscales.

overall_energy
Explainable Longevity Score Decomposition

Score Breakdown: 88 / 100

Confidence Interval:±3.2%
Synergy Multiplier:1.25x
Evidence Strength89/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude92/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index85/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit82/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility86/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Superior preservation of endogenous HPTA axis, fertility, and testicular volume compared to exogenous testosterone replacement therapy in secondary hypogonadal men.

Practicality, Cost & Adherence Index

Monthly Cost
$30–$100 / month
Time Commitment
1 min/day
~0.12 hrs/week
Adherence Friction
2/10
Effortless (Habitual)
Accessibility
prescription
Granular Clinical Study Ledger

Enclomiphene Citrate (Selective Estrogen Receptor Modulator) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
2
Human RCTs
2
Pooled N
248
Avg RoB
1.1 / 5
Human Clinical (n=124)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.1

Oral enclomiphene citrate stimulates the secretion of luteinizing hormone and testosterone while maintaining normal sperm counts in men with secondary hypogonadism: a randomized, double-blind, multicenter, phase II study

Kaminetsky J, Werner M, Fontenot G, Wiehle RD.•BJU International•2013•N = 124•16 wks
Intervention Protocol: Oral enclomiphene citrate (12.5 mg and 25 mg daily) vs 1% topical testosterone gel vs placebo
Quantitative Endpoints & Effect Sizes
Total Serum Testosterone Elevation+143.5%
Increased from mean 248 ng/dL to 604 ng/dL in 25mg cohort within normal eugonadal rangep < 0.001
Serum Luteinizing Hormone (LH) and FSH+110%
Elevated LH and FSH demonstrating hypothalamic-pituitary-gonadal (HPG) axis disinhibitionp < 0.0001
Sperm Concentration Preservation+4.2%
Sperm counts remained fully normal (vs marked oligospermia in 54% of topical testosterone arm)p < 0.0001
Clinical Takeaway:Proved in a multicenter randomized double-blind Phase II trial that oral enclomiphene citrate raises endogenous testosterone and gonadotropins (LH/FSH) to normal physiological ranges while preserving normal testicular spermatogenesis, completely avoiding the azoospermia caused by exogenous TRT.
Independent Academic Research
PubMed: 23879796DOI
Human Clinical (n=124)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.2

Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized Phase II clinical trial in men with secondary hypogonadism

Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Niederberger C.•The Journal of Clinical Endocrinology & Metabolism•2014•N = 124•16 wks
Intervention Protocol: Oral enclomiphene citrate (12.5 mg or 25 mg daily) vs transdermal testosterone gel (5 g/50 mg)
Quantitative Endpoints & Effect Sizes
Morning Total Testosterone Eugonadal Normalization+122%
Morning testosterone normalized in 92% of men without suppressing pituitary trophic drivep < 0.001
Follicle-Stimulating Hormone (FSH) Secretion+85%
Sustained Sertoli cell trophic stimulation maintaining viable gametogenesisp < 0.001
Clinical Takeaway:Demonstrated that enclomiphene citrate reliably normalizes morning testosterone in secondary hypogonadal men while sustaining Sertoli cell stimulation and preventing the suppression of pituitary gonadotropins and sperm counts seen with exogenous androgens.
Independent Academic Research
PubMed: 25055002DOI
Chronological Evolution of Evidence

Enclomiphene Citrate (Selective Estrogen Receptor Modulator) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Enclomiphene Citrate (Selective Estrogen Receptor Modulator) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •Active prostate carcinoma or breast cancer
  • •Primary testicular failure with high baseline LH/FSH
  • •Severe hepatic impairment
  • •Pregnancy or nursing

Pharmacological & Supplement Interactions

Aromatase Inhibitors (Anastrozole)moderate Risk

Excessive suppression of estradiol below 20 pg/mL impairs bone mineral density, lipid profiles, and libido.

Exogenous Androgens / Anabolic Steroidshigh Risk

Exogenous testosterone suppresses pituitary gonadotropins, directly counteracting enclomiphene mechanism of action.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • •Mild transient visual floaters or blurring in rare cases (<1%)
  • •Modest increase in serum estradiol proportional to testosterone rise
  • •Mild headache or nausea
Speculative / Theoretical Long-Term Concerns:
  • •Thromboembolic risk typical of estrogen receptor modulators at high supratherapeutic doses

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Long-term cardiovascular outcomes beyond 5 years of continuous use
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.25x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)